These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 27091406)
1. Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities. Jonas O; Oudin MJ; Kosciuk T; Whitman M; Gertler FB; Cima MJ; Flaherty KT; Langer R Clin Cancer Res; 2016 Dec; 22(24):6031-6038. PubMed ID: 27091406 [TBL] [Abstract][Full Text] [Related]
2. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251 [TBL] [Abstract][Full Text] [Related]
3. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033 [TBL] [Abstract][Full Text] [Related]
4. PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo. Niessner H; Schmitz J; Tabatabai G; Schmid AM; Calaminus C; Sinnberg T; Weide B; Eigentler TK; Garbe C; Schittek B; Quintanilla-Fend L; Bender B; Mai M; Praetorius C; Beissert S; Schackert G; Muders MH; Meinhardt M; Baretton GB; Dummer R; Flaherty K; Pichler BJ; Kulms D; Westphal D; Meier F Clin Cancer Res; 2016 Dec; 22(23):5818-5828. PubMed ID: 27307593 [TBL] [Abstract][Full Text] [Related]
5. Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Krepler C; Xiao M; Sproesser K; Brafford PA; Shannan B; Beqiri M; Liu Q; Xu W; Garman B; Nathanson KL; Xu X; Karakousis GC; Mills GB; Lu Y; Ahmed TA; Poulikakos PI; Caponigro G; Boehm M; Peters M; Schuchter LM; Weeraratna AT; Herlyn M Clin Cancer Res; 2016 Apr; 22(7):1592-602. PubMed ID: 26673799 [TBL] [Abstract][Full Text] [Related]
6. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma. Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478 [TBL] [Abstract][Full Text] [Related]
7. Downregulation of lncRNA TSLNC8 promotes melanoma resistance to BRAF inhibitor PLX4720 through binding with PP1α to re-activate MAPK signaling. Han Y; Fang J; Xiao Z; Deng J; Zhang M; Gu L J Cancer Res Clin Oncol; 2021 Mar; 147(3):767-777. PubMed ID: 33389075 [TBL] [Abstract][Full Text] [Related]
8. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Deng W; Gopal YN; Scott A; Chen G; Woodman SE; Davies MA Pigment Cell Melanoma Res; 2012 Mar; 25(2):248-58. PubMed ID: 22171948 [TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489 [TBL] [Abstract][Full Text] [Related]
11. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714 [TBL] [Abstract][Full Text] [Related]
12. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells. Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806 [TBL] [Abstract][Full Text] [Related]
13. Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy. Talebi A; Dehairs J; Rambow F; Rogiers A; Nittner D; Derua R; Vanderhoydonc F; Duarte JAG; Bosisio F; Van den Eynde K; Nys K; Pérez MV; Agostinis P; Waelkens E; Van den Oord J; Fendt SM; Marine JC; Swinnen JV Nat Commun; 2018 Jun; 9(1):2500. PubMed ID: 29950559 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma. Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853 [TBL] [Abstract][Full Text] [Related]
15. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF Hong SP; Ahn SK Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859 [TBL] [Abstract][Full Text] [Related]
16. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. Yao TW; Zhang J; Prados M; Weiss WA; James CD; Nicolaides T Oncotarget; 2015 Sep; 6(26):21993-2005. PubMed ID: 26023796 [TBL] [Abstract][Full Text] [Related]
17. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors. Delmas A; Cherier J; Pohorecka M; Medale-Giamarchi C; Meyer N; Casanova A; Sordet O; Lamant L; Savina A; Pradines A; Favre G Oncotarget; 2015 Jun; 6(17):15250-64. PubMed ID: 26098773 [TBL] [Abstract][Full Text] [Related]
18. c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition. Byeon HK; Na HJ; Yang YJ; Kwon HJ; Chang JW; Ban MJ; Kim WS; Shin DY; Lee EJ; Koh YW; Yoon JH; Choi EC Mol Carcinog; 2016 Nov; 55(11):1678-1687. PubMed ID: 26456083 [TBL] [Abstract][Full Text] [Related]
19. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024 [TBL] [Abstract][Full Text] [Related]
20. MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor. Aida S; Sonobe Y; Tanimura H; Oikawa N; Yuhki M; Sakamoto H; Mizuno T Cancer Lett; 2017 Nov; 409():116-124. PubMed ID: 28923400 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]